Work

Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1. The effects of G1T28 are due to CDK4/6 inhibition. Supplemental Figure 2. Analysis of pharmacodynamics endpoints indicates on-target activity in 22Rv1 tumors. A. Supplemental Figure 3. G1T38 and G128 have similar in vitro efficacy. Supplemental Figure 4. G1T28 inhibits anti-androgen stimulated prostate cancer cell growth.

DOI: 10.1158/1541-7786.22516801.v1

Authors: James P. Stice, Suzanne E. Wardell, John D. Norris, Alexander P. Yllanes, Holly M. Alley, Victoria O. Haney, Hannah S. White, Rachid Safi, Peter S. Winter, Kimberly J. Cocce, Rigel J. Kishton, Scott A. Lawrence, Jay C. Strum, Donald P. McDonnell

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362487137

Cites:

Cited by:

Related to: 10